Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).
Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).
复制标题
使用侵入性循环肿瘤细胞（ICTC）对上皮卵巢癌患者的治疗监测。
DOI：
10.1016/j.ygyno.2015.03.002
复制
发表时间：
2015-05
影响因子：
4.7
通讯作者：
Chen WT
中科院分区：
文献类型：
--
作者：
Pearl ML;Dong H;Tulley S;Zhao Q;Golightly M;Zucker S;Chen WT
上皮性卵巢癌（EOC）的当代管理使用生物标志物来监测对治疗的反应。本研究评估了侵袭性循环肿瘤细胞（ictc）在监测EOC治疗中的作用，并与血清癌抗原125 （CA125）进行了比较。分子和显微分析鉴定了seprase和CD44作为肿瘤祖细胞（TP）的标志物。采用64名健康献血者、49名腹部良性疾病患者和123名EOC患者的血液，对iCTC流式细胞术检测方法进行了优化。在31例EOC患者的129份血液和169份血清样本中分别测量ictc和CA125的一系列变化，以评估其在治疗期间的一致性及其与疾病进展（PD）风险的关系。该方法检测EOC患者血液中ictc的特异性为97%，敏感性为83%。每个监测患者（31/ 31,100 %）检测到ictc， 129份血样中有110份（85.3%）检测到ictc。ictc / CA125水平变化与无疾病证据相关的间隔变化（NED）之间的一致性明显更强（特异性：CA125 93.8%; ictc 90.6%），而ictc升高（79.5%）比CA125升高（67.6%）对预测PD或复发更敏感。在6例测量值大于6的患者中，ictc而非CA125预示着化疗期间和化疗后PD到NED的临床状态的变化，并预示着复发。连续测量ictc可预测31例接受标准紫杉醇/卡铂治疗的EOC患者的治疗反应性。
Contemporary management of epithelial ovarian cancer (EOC) uses biomarkers to monitor response to therapy. This study evaluates the role of invasive circulating tumor cells (iCTCs) in monitoring EOC treatment in comparison with serum cancer antigen 125 (CA125). Molecular and microscopic analyses were used to identify seprase and CD44 as tumor progenitor (TP) markers. The iCTC flow cytometry assay was optimized using blood donated by 64 healthy donors, 49 patients with benign abdominal diseases and 123 EOC patients. Serial changes in iCTCs and CA125 were measured in 129 blood and 169 serum samples, respectively, from 31 EOC patients to assess their concordance during therapy and their relationship with risk of progressive disease (PD). The assay had 97% specificity and 83% sensitivity for detecting iCTCs in blood of EOC patients. iCTCs were detected in each monitoring patient (31/31, 100%) and in 110 of the 129 blood samples (85.3%). The concordance between changes in iCTCs / CA125 levels and changes in the intervals associated with no evidence of disease (NED) were markedly stronger (specificity: CA125 93.8%; iCTCs 90.6%), whereas increases in iCTCs (79.5%) were more sensitive than increases in CA125 (67.6%) to predict PD or relapse. Among the six patients who had greater than 6 measurements, iCTCs but not CA125 antedated changes in clinical status from PD to NED during and after chemotherapy, and predated relapse. Serial measurements of iCTCs could predict therapeutic responsiveness in 31 EOC patients who underwent standard taxol / carboplatin therapy.
登录
查看更多内容
影响因子：
158.5
作者：
Cristofanilli, M;Budd, GT;Hayes, DF
通讯作者：
Hayes, DF
影响因子：
11.1
作者：
Joosse SA;Gorges TM;Pantel K
通讯作者：
Pantel K
影响因子：
11.2
作者：
Chen, Donghai;Kennedy, Alanna;Chen, Wen-Tien
通讯作者：
Chen, Wen-Tien
影响因子：
4.8
作者：
Hailpern, Susan M.;Visintainer, Paul F.
通讯作者：
Visintainer, Paul F.
EP-CAM：人类上皮抗原是一种同粒细胞粘附分子。
影响因子：
7.8
作者：
Litvinov, S V;Velders, M P;Bakker, H A;Fleuren, G J;Warnaar, S O
通讯作者：
Warnaar, S O